Romania’s state-controlled pharmaceutical company **Antibiotice** reports a **73.8% year-on-year decline in net profit** for the first half of 2026. The company’s earnings fall to **15.5 million lei** ($3.43 million) amid financial challenges. The drop reflects broader pressures on state-owned enterprises in Romania’s pharmaceutical sector.
BT Group provides a €67 million investment to **Antibiotice Iași**, a Romanian pharmaceutical manufacturer. The funding supports expansion of production capacity for antibiotics and other critical medicines. The company aims to strengthen its position in the European market with the additional capital.
The **European Investment Bank (EIB)** is advising **Antibiotice SA**, Romania’s largest domestically owned pharmaceutical company, on improving corporate governance to drive future expansion. The advisory agreement focuses on aligning Antibiotice’s risk-management systems and operational practices with global pharmaceutical industry standards. The initiative aims to enhance the company’s investment capacity and operational resilience.
Romania’s state-controlled pharmaceutical company **Antibiotice** is advancing plans to build a **75 million euro research and development (R&D) center** for critical medicines. The initiative aims to strengthen domestic production capabilities for essential drugs. Construction is set to begin this year, marking a significant investment in Romania’s healthcare infrastructure.
